<div id="readability-page-1"><div><ul> <li>Vera Therapeutics, Inc. reported first-quarter 2026 results, posting a net loss of US$121.03 million, compared with US$51.69 million a year earlier, and a basic loss per share from continuing operations of US$1.69 versus US$0.81.</li> <li>The sharp year-on-year increase in both total net loss and loss per share highlights rising costs or investments that are weighing more heavily on the company’s income statement.</li> <li>Next, we’ll examine how this widening net loss shapes Vera Therapeutics’ investment narrative and what it may signal about its operating trajectory.</li> </ul><p>We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.</p><h2>What Is Vera Therapeutics' Investment Narrative?</h2><p>To own Vera Therapeutics today, you have to believe that atacicept’s potential in IgA nephropathy and related kidney diseases ultimately outweighs the company’s mounting losses and ongoing dilution. The latest first quarter 2026 result, with net loss more than doubling to US$121.03 million, reinforces that this is very much a pre-revenue, cash-consuming story ahead of the July 2026 PDUFA decision. In the near term, that FDA outcome and any clarity on commercialization plans remain the key catalysts, while the steeper loss profile raises the importance of balance sheet strength and future funding terms. Recent share price weakness suggests the market is starting to price in higher execution and financing risk, and this earnings step-up now sits squarely in the middle of that debate.</p><p> However, the jump in quarterly loss also brings a funding and dilution risk that investors should not ignore.  Despite retreating, Vera Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.</p><h2>Exploring Other Perspectives</h2><p> Four Simply Wall St Community estimates span roughly US$44 to a very large US$442 per share, underscoring how differently people see Vera’s potential while its widening losses and upcoming PDUFA date remain front and center for the company’s fortunes.</p><p>Explore 4 other fair value estimates on Vera Therapeutics - why the stock might be worth just $44.21!</p><h2>Reach Your Own Conclusion</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Vera Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Vera Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vera Therapeutics' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the 45 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li><li>This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.</li><li>The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

VERA

ARKG

LABU

<p>Vera Therapeutics reported a Q1 2026 net loss of $121.03 million, up from $51.69 million a year prior, with a loss per share of $1.69. This significant increase highlights rising costs impacting the company's financials. Investors must weigh the potential of atacicept against these losses as the July 2026 PDUFA decision approaches. The widening losses raise concerns about funding and dilution risks, with share prices potentially above fair value amidst market volatility.</p>

Simplywall

Vera Therapeutics

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VG Health

iShares Global Healthcare

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden